Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Significance of Heterozygosity for Mutations of the SLC12A3 Gene Coding for the Thiazide Sensitive Na-Cl Cotransporter

NCT02035046 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT02035046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02035046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Significance of Heterozygosity for Mutations of the SLC12A3 Gene Coding for the Thiazide Sensitive Na-Cl Cotransporter
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Not applicable
Overall status
Completed
Start date
December 31, 2013
Completion date
September 30, 2016
Enrollment
250 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

heterozygous carriers of gitelman syndrome